Presence of Unmet Needs to Create Opportunities for the Global Premature Ejaculation Treatment Market Through 2020, Reports Technavio

LONDON–(BUSINESS WIRE)–#HealthAndWellnessTechnavio
analysts forecast the global
premature ejaculation treatment market
to grow at a CAGR
of close to 10% during the forecast period, according to their latest
report.

The research study covers the present scenario and growth prospects of
the global premature
ejaculation treatment
market for 2016-2020. The report
lists three main end-user segments which are individuals, physicians,
hospitals and pharmaceutical companies.

Premature ejaculation occurs in more than 30% of men worldwide due
to neuro-physiological causes. Premature ejaculation treatment is
considered a taboo subject in various regions, resulting in many online
entrepreneurs and investors selling their products and solutions through
e-commerce, which helps maintain the anonymity of the customer.

The prevalence rate of premature ejaculation is high in countries such
as the US, Canada, and Australia, mainly due to the high number of
chronic diseases such as diabetes and cancer in these countries. Some of
the effective treatments available to treat the condition are
psychological counselling, medications, sexual techniques that delay
ejaculation, and a combination of these treatments.

Technavio analysts highlight the following four factors that are
contributing to the growth of the global premature ejaculation treatment
market:

  • Proliferation of strategic initiatives
  • Rise in number of erectile dysfunction cases
  • Presence of unmet needs
  • High prevalence rate of cancer among men

Proliferation of strategic initiatives

There has been an increase in the number of strategic initiatives
related to the premature ejaculation treatment market, which has
significantly influenced the growth of the market. Premature ejaculation
solution providers worldwide aim to leverage each other’s USPs,
resulting in various partnerships between companies. They take advantage
of the customer base, technology, financial capability, and R&D
capabilities of their partners to increase market share and strongly
establish their presence in the market. For instance, in September 2013
Innovus Pharma entered into a license and distribution agreement with
Ovation and granted the company an exclusive license to market and sell
its product EjectDelay in Morocco to expand its presence in EMEA.
Likewise, in July 2014, Royalty Pharma acquired the rights of Priligy
from Allergan with the purpose of expanding its product portfolio and
establishing its presence in the premature ejaculation treatment market.

These types of strategic initiatives help vendors add products to the
existing product portfolio. They have also helped companies venture into
untapped markets, especially in developing countries, and increase their
geographical reach by launching products with the help of the local
player’s market presence.

Rise in number of erectile dysfunction cases

The rapidly increasing number of erectile dysfunction cases has become a
global concern. According to a report published by CNN, the number of
such cases witnessed a staggering increase of 165% during 2002-2010. Erectile
dysfunction
is considered a possible cause of premature
ejaculation among men.

Erectile dysfunction is caused by factors such as high blood pressure,
diabetes, atherosclerosis, obesity, heart and blood vessel diseases,
multiple sclerosis, chronic kidney disease, surgery for bladder cancer
and prostate cancer, and Peyronie’s disease. These diseases affect
sexual arousal, which happens through a coordination of hormones,
emotions, muscles, nerves, and blood vessels, thereby hampering the
erection level of men. Erectile dysfunction can cause unsatisfactory sex
lives, which leads to stress, anxiety, and low self-esteem, ultimately
resulting in premature ejaculation during sexual intercourse. Therefore,
an increase in the number of erectile dysfunction cases has also
increased the chances of men being affected by premature ejaculation.
“The condition can be diagnosed through various methods and tests,
including studying medical and sexual history, physical exams, blood
tests, injection tests, nocturnal erection tests, Doppler ultrasounds,
and mental health exams,” says Amber Chourasia, a lead analyst at
Technavio for health
and wellness
research.

Presence of unmet needs

Currently, there are only a few approved therapies available in the
market for premature ejaculation indication. They include Priligy,
Tempe, Promescent, and EjectDelay. The small number of recognized drugs
available to treat premature ejaculation indicates that a significant
opportunity exists for new entrants to capitalize on the potential in
the market. This is attracting many big pharmaceutical companies to
invest in R&D programs and develop new solutions. For instance, the
pharmaceutical company GlaxoSmithKline is currently developing
Epelsiban, an oral drug for treating premature ejaculation. It is
expected to be available in a couple of years.

The development and approval of drugs from various regulatory bodies for
the treatment of premature ejaculation will significantly lessen the
dependence of patients on off-label treatments such as PDE5 inhibitors,
which include tadalafil (Cialis), sildenafil (Viagra), and vardenafil
(Levitra). “Patients who are not responding to the treatments available
at present become an untapped area of R&D for many pharmaceutical
companies, which aim to introduce unique and novel drugs into the global
premature ejaculation treatment market,” says Amber.

High prevalence rate of cancer among men

Cancer is a probable cause of premature ejaculation among men. Cancer
treatment can lead to a change in hormonal functioning and sex hormones
(androgens such as testosterone), which eventually affects the libido
and the ability of men to achieve orgasms during sexual intercourse.

Generally, cancer
requires treatments such as surgery, radiotherapy, and chemotherapy to
completely eradicate the disease in the patient or to limit the spread
of cancer cells. In many cases, chemotherapy among men has been known to
impede the production of testosterone, thus affecting the overall sexual
response and desire. Therefore, the increase in the number of cases of
cancer among men raises the probability of premature ejaculation cases.

Browse Related Reports:

Do you need a report on a market in a specific geographical cluster
or country but can’t find what you’re looking for? Don’t worry,
Technavio also takes client requests. Please contact
enquiry@technavio.com
with your requirements and our analysts will be happy to create a
customized report just for you.

About Technavio

Technavio
is a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com